Skip to main content
NewslettersWatchlist

Portage Biotech Inc Ord(PRTG-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low3.80
Day High4.22
Open:4.19
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Baystreet
Portage Down on Announcing Alternatives
Globe Newswire
UPDATE -- Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022
Globe Newswire
Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022
Globe Newswire
Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
Globe Newswire
Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway
Globe Newswire
Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study
Globe Newswire
Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity
Globe Newswire
Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting
Globe Newswire
Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting
Globe Newswire
Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year
Globe Newswire
Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year
Globe Newswire
Portage Biotech to Present at the Piper Sandler 33rd Annual Healthcare Conference
Globe NewsWire
Portage Biotech Announces Participation in September 2021 Investor Conferences
Globe NewsWire
Portage Biotech Announces Results for First Quarter of 2022 Fiscal Year
Globe NewsWire
Portage Biotech Issues Letter to Shareholders
Globe NewsWire
Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (NSCLC)
Globe NewsWire
Portage Biotech Announces Results for Fiscal Year Ended March 31, 2021

Profile

Portage Biotech Inc. is a clinical stage immuno-oncology company focused on overcoming immune resistance. The company source, nurture and develop therapies for a variety of cancers. Its drug development pipeline portfolio encompasses products or technologies with established scientific rationales, including intratumorals, nanoparticles, liposomes, aptamers, cell penetrating peptides, and virus-like particles. Portage Biotech Inc. is based in Tortola, British Virgin Islands.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.